191 related articles for article (PubMed ID: 36857853)
41. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
[TBL] [Abstract][Full Text] [Related]
42. Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.
Garjani A; Patel S; Bharkhada D; Rashid W; Coles A; Law GR; Evangelou N
Mult Scler Relat Disord; 2022 Jan; 57():103458. PubMed ID: 34896876
[TBL] [Abstract][Full Text] [Related]
43. Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic.
Coyle PK; Gorritz M; Wade RL; Zhou Z; Khalid S; Maiese EM; Deshpande C; Shao QS
Mult Scler Relat Disord; 2023 Oct; 78():104881. PubMed ID: 37556938
[TBL] [Abstract][Full Text] [Related]
44. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
[TBL] [Abstract][Full Text] [Related]
45. Rituximab for people with multiple sclerosis.
Filippini G; Kruja J; Del Giovane C
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013874. PubMed ID: 34748215
[TBL] [Abstract][Full Text] [Related]
46. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
47. A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
Lal AP; Foong YC; Sanfilippo PG; Spelman T; Rath L; Levitz D; Fabis-Pedrini M; Foschi M; Habek M; Kalincik T; Roos I; Lechner-Scott J; John N; Soysal A; D'Amico E; Gouider R; Mrabet S; Gross-Paju K; Cárdenas-Robledo S; Moghadasi AN; Sa MJ; Gray O; Oh J; Reddel S; Ramanathan S; Al-Harbi T; Altintas A; Hardy TA; Ozakbas S; Alroughani R; Kermode AG; Surcinelli A; Laureys G; Eichau S; Prat A; Girard M; Duquette P; Hodgkinson S; Ramo-Tello C; Maimone D; McCombe P; Spitaleri D; Sanchez-Menoyo JL; Yetkin MF; Baghbanian SM; Karabudak R; Al-Asmi A; Jakob GB; Khoury SJ; Etemadifar M; van Pesch V; Buzzard K; Taylor B; Butzkueven H; Van der Walt A
J Neurol; 2024 Jun; ():. PubMed ID: 38935148
[TBL] [Abstract][Full Text] [Related]
48. Treatment selection and experience in multiple sclerosis: survey of neurologists.
Hanson KA; Agashivala N; Wyrwich KW; Raimundo K; Kim E; Brandes DW
Patient Prefer Adherence; 2014; 8():415-22. PubMed ID: 24729689
[TBL] [Abstract][Full Text] [Related]
49. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.
Simacek KF; Ko JJ; Moreton D; Varga S; Johnson K; Katic BJ
J Med Internet Res; 2018 Oct; 20(10):e11168. PubMed ID: 30377144
[TBL] [Abstract][Full Text] [Related]
50. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviors and access to disease-modifying therapies.
Beesley R; Cauchi M; Davies L; Upcott M; Norton E; Loveless S; Anderson V; Wynford-Thomas R; Pickersgill TP; Uzochukwu E; Wardle M; Robertson NP; Tallantyre E; Willis MD
Mult Scler Relat Disord; 2022 Dec; 68():104121. PubMed ID: 36088727
[TBL] [Abstract][Full Text] [Related]
51. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
English C; Aloi JJ
Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
[TBL] [Abstract][Full Text] [Related]
52. Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010-2019.
Zhu W; Tang X; Heyman RA; Cai T; Suh K; Seeger JD; Xia Z
Neurol Ther; 2022 Sep; 11(3):1147-1165. PubMed ID: 35598225
[TBL] [Abstract][Full Text] [Related]
53. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.
MacDonald SC; McElrath TF; Hernández-Díaz S
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):556-560. PubMed ID: 30834654
[TBL] [Abstract][Full Text] [Related]
54. Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients.
Freeman L; Kee A; Tian M; Mehta R
Clinicoecon Outcomes Res; 2021; 13():65-75. PubMed ID: 33519217
[TBL] [Abstract][Full Text] [Related]
55. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
56. The effect of the COVID-19 pandemic on the prescribing of opioid and opioid use disorder medications within an academic medical center in California.
Fstkchian AK; Koch J; Bahjri K; Hong LT
Front Public Health; 2023; 11():1105681. PubMed ID: 37351093
[TBL] [Abstract][Full Text] [Related]
57. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
Johnston J; So TY
Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
[TBL] [Abstract][Full Text] [Related]
58. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
59. Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis.
Reyes S; Suarez S; Allen-Philbey K; Yildiz Ö; Mathews J; Anjorin G; Edwards F; Jain C; Turner B; Marta M; Gnanapavan S; Schmierer K; Giovannoni G
Mult Scler Relat Disord; 2020 Jun; 41():102024. PubMed ID: 32143179
[TBL] [Abstract][Full Text] [Related]
60. Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS).
Stamatellos VP; Papazisis G
Curr Rev Clin Exp Pharmacol; 2023; 18(1):39-50. PubMed ID: 35418296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]